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In this study, we set out to establish whether fludarabine could enhance the DNA interstrand crosslinking capacity of SJG-136 in
primary human chronic lymphocytic leukaemia (CLL) cells and thereby offer a rationale for its clinical use in combination with SJG-
136. SJG-136 rapidly induced DNA crosslinking in primary CLL cells which was concentration-dependent. Further, the level of
crosslinking correlated with sensitivity to SJG-136-induced apoptosis (P¼0.001) and higher levels of crosslinking were induced by the
combination of SJG-136 and fludarabine (P¼0.002). All of the samples tested (n¼40) demonstrated synergy between SJG-136 and
fludarabine (mean combination index (CI)¼0.5470.2) and this was even retained in samples derived from patients with fludarabine
resistance (mean CI¼0.6270.3). Transcription of the excision repair enzyme, ERCC1, was consistently increased (20/20) in
response to SJG-136 (Po0.0001). In contrast, fludarabine suppressed ERCC1 transcription (P¼0.04) and inhibited SJG-136-induced
ERCC1 transcription when used in combination (P¼0.001). Importantly, the ability of fludarabine to suppress ERCC1 transcription
correlated with the degree of synergy observed between SJG-136 and fludarabine (r
2¼0.28; P¼0.017) offering a mechanistic
rationale for the synergistic interaction. The data presented here provides a clear indication that this combination of drugs may have
clinical utility as salvage therapy in drug-resistant CLL.
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B-cell chronic lymphocytic leukaemia (CLL) is an incurable
malignancy with a variable clinical course (Bosch and Montserrat,
2002). Outcome for advanced-stage CLL patients is poor, with an
expected median survival of 3 years (Lee et al, 1987). Although the
introduction of purine nucleoside analogues (Zhu et al, 2004) and
monoclonal antibody therapies (Byrd et al, 2001; Keating et al,
2002), either as single agents or in combination (Byrd et al, 2003;
Kay, 2006), has led to significantly increased response rates, none
of these options is curative. Consequently, there is a need to
identify new agents for the treatment of CLL, particularly agents
that have the potential to complement existing therapeutic options
and overcome drug resistance.
SJG-136 (NSC 694501, BN2629, SG2000) is a novel DNA
crosslinking agent that binds in a sequence-specific manner the
minor groove of the helix (Gregson et al, 2001; Hartley et al, 2004).
It is structurally novel compared to other clinically used DNA
crosslinking agents and has exhibited a unique multilog differ-
ential pattern of activity in the NCI 60 cell line screen (Hartley
et al, 2004). SJG-136 also displayed potent activity against several
human tumours in vivo (Alley et al, 2004), and phase I clinical
trials against both solid tumours and haematological malignancies
are currently underway. We have previously shown that SJG-136 is
extremely cytotoxic to CLL cells in vitro, exhibiting LD50 values
more than 2logs lower than fludarabine, the current treatment of
choice for this condition (Pepper et al, 2004). Furthermore, SJG-
136 exhibited differential cytotoxicity since it was less effective at
inducing apoptosis in normal B- and T-lymphocytes derived from
CLL patients.
The formation of drug-induced crosslinks between two comple-
mentary strands of DNA, interstrand crosslinking (ICL), is con-
sidered to be critical to the activity of bifunctional alkylating agents,
and there is clear evidence that their formation and subsequent
persistence correlates to in vitro cytotoxicity (Sunters et al,1 9 9 2 ) .I n
this context, it has been previously demonstrated that fludarabine can
inhibit excision and repair of ICL and by so doing contributes to the
synergy observed between fludarabine and cisplatin (Yang et al, 1995;
Li et al, 1997). This inhibition of ICL repair was associated with
the inhibition of the nucleotide excision repair enzyme, ERCC1. In
addition, a recent report clearly demonstrated a role for ERCC1 in the
repair of SJG-136-induced DNA ICLs (Clingen et al, 2005). Therefore,
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sthis present study was designed to investigate whether fludarabine-
mediated inhibition of ERCC1-mediated DNA repair could positively
impact on SJG-136 ICL patterns and enhance the resulting
cytotoxicity of SJG-136 in CLL cells.
MATERIALS AND METHODS
Patients’ cells and clinical details
Peripheral blood samples from 40 patients with CLL were obtained
with the patients’ written informed consent in accordance with the
conditions for ethical approval granted by the Southeast Wales
Research Ethics Committee (no. 02/4806). Chronic lymphocytic
leukaemia was defined by clinical criteria, and staging was based
on the Binet system (Binet et al, 1981). None of the previously
treated patients had received therapy for at least 1 month before
the study. VH gene mutational status, CD38 expression and ZAP-70
expression was available for all of the patients under investigation.
The clinical characteristics of the patient cohort are summarised in
Table 1.
Primary CLL cell-culture conditions
Freshly isolated peripheral blood lymphocytes (1 10
6ml
 1) were
cultured in RPMI medium (Invitrogen, Paisley, UK), supplemented
with 100Uml
 1 penicillin, 100mgml
 1 streptomycin and 10% fetal
calf serum. Lymphocytes were incubated at 371C in a humidified
5% carbon dioxide atmosphere in the presence of SJG-136 (10
 10–
10
 7 M), fludarabine (10
 7–10
 5 M) or both drugs in combination
at fixed molar ratio of 1:100 (SJG-136:fludarabine). The optimal
ratio for synergy between the two agents was determined
experimentally (data not shown). In addition, control cultures
were carried out to which no drug was added. All experiments were
performed in duplicate.
Single-cell gel electrophoresis assay
The level of DNA ICL was determined using a modified single-cell
gel electrophoresis (comet) assay (Hartley et al, 1999; Spanswick
et al, 2002). Each sample was split into two for the separate
analysis of single-strand breaks and DNA ICL. The sample for
crosslink analysis was irradiated (12.5Gy, 2.35Gymin
 1) imme-
diately before analysis to deliver a fixed number of random DNA-
strand breaks. After embedding cells in 1% agarose the cells were
lysed for 1h in lysis buffer and then washed for 1h in distilled
water. Slides were then incubated in alkali buffer for 45min
followed by electrophoresis in the same buffer for 25min.
After drying, the slides were stained with propidium iodide for
30min then rinsed in distilled water. Images were captured
using an online CCD camera and analysed using Komet Analysis
software (Kinetic Imaging, Liverpool, UK). For each duplicate
slide, 25 cells were analysed. The tail moment for each image was
calculated using the Komet Analysis software as the product of the
percentage DNA in the comet tail and the distance between the
means of the head and tail distributions, based on the definition of
Olive et al (1990). Crosslinking was expressed as the percentage
decrease in tail moment compared to irradiated controls and was
calculated using the formula
%decreaseintailmoment ¼ 1  
TMdi   TMcu
TMci   TMcu
 
 100
where TMdi is the tail moment of drug-treated irradiated sample,
TMcu the tail moment of untreated, unirradiated control, and
TMci the tail moment of untreated, irradiated.
In combination studies of SJG-136 and fludarabine, the
following formula was used:
%decreaseintailmoment ¼
1  
ðTMdi   TMcuÞ
ðTMci   TMcuÞþð TMdu   TMcuÞ
 
 100
where TMdu is the tail moment of drug-treated, unirradiated
samples to take into account any extra strand breaks produced by
fludarabine.
Measurement of in vitro apoptosis
Cultured cells were harvested by centrifugation. Apoptosis was
assessed by dual-colour immunofluorescent flow cytometry as
described previously (Vermes et al, 1997; Pepper et al, 2003).
Assessment of synergy between SJG-136 and fludarabine
Cells were incubated with various concentrations of fludarabine,
SJG-136 and fludarabine in an optimised fixed-ratio combination
with SJG-136 for 48h at 371C. Dose–response curves were plotted
for each individual drug and drug combination, and the curves
were analysed using the median effect method to determine the
degree of synergy (Chou and Talalay, 1984). These experiments
were conducted in two groups of samples, that is those derived
from patients who had demonstrated either in vitro and/or clinical
resistance to fludarabine (20 patients) and CLL samples that
retained sensitivity to fludarabine (20 patients) to assess the drug
interactions in each cohort.
RT–PCR analysis of ERCC1 transcription
Total RNA was extracted from 3 10
7 CLL lymphocytes using
RNeasy spin columns according to the manufacturer’s instructions
(Qiagen, Crawley, UK). One microgram of total RNA was then
reverse-transcribed using a Clontech first-strand cDNA synthesis
kit (Clontech, Between Towns, Cowley, Oxford, UK). Subsequently,
real-time PCR was performed using ERCC1-specific primers
CCGCCAGCAAGGAAGAAATT (forward) and TTACGTCGCC
AAATTCCCAG (reverse) and S14 (house-keeping gene) primers
GGCAGACCGAGATGAACTCT (forward) and CCAGGTCCAGGG
GTCTTGGT (reverse) in PCR buffer containing 50nM of each
primer, 4.0mM MgCl2 cDNA template and FastStart SYBR Green I
DNA master mix (Roche Diagnostics, Welwyn Garden City,
Hertfordshire, UK) in a 10ml final volume. Each reaction was
cycled 45 times consisting of a 10s denaturation (951C), 5s
annealing (601C) and 20s extension (721C). To confirm the
amplification specificity the PCR products were subjected to
melting-curve analysis. The S14:ERCC1 transcription ratio was
calculated from the crossing points of each gene.
Statistical analysis
The data obtained in these experiments were subjected to the
Kolmorgorov–Smirnov test of normality; all the data sets tested
were shown to be Gaussian. Consequently, statistical analyses
were performed using the paired Student’s t-test. Correlation
Table 1 Clinical characteristics of the CLL patients in this study
No. of patients 40
Mean age (years) 64
Sex (male/female) 25/15
Binet stage (A/B/C) 13/9/18
Previous treatment (untreated/treated) 24/16
Clinical resistance to fludarabine (resistant/sensitive) 9/16
VH gene mutation (mutated/unmutated) 18/22
CD38 expression (o30%/X30%) 17/23
ZAP-70 expression (o20%/X20%) 15/25
CLL¼chronic lymphocytic leukaemia.
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scoefficients were calculated from least-squares linear regression
plots, and drug sensitivity was evaluated using nonlinear regression
and line of best-fit analysis of the sigmoidal dose–response curves.
All statistical analyses were performed using Graphpad Prism 3.0
software (Graphpad Software Inc., San Diego, CA, USA). Synergy
was assessed using Calcusyn software (Biosoft, Cambridge, UK).
RESULTS
SJG-136-induced DNA ICL
The level of DNA ICL was determined using a modification of the
comet assay. Figure 1A shows the mean (7s.d.) percentage
decrease in tail moment in CLL samples derived from 10 patients
following exposure to 2 and 4nM SJG-136 for 24h. A decrease in
tail moment has previously been shown to reflect an increase in
DNA ICL (Hartley et al, 1999). Therefore, SJG-136 was shown to be
a potent ICL agent in all the CLL samples tested with a mean
concentration of SJG-136 that caused a 50% decrease in tail
moment of approximately 2.6nM. Importantly, the degree of DNA
crosslinking was correlated with in vitro sensitivity to SJG-136 as
determined by measurement of apoptosis using Annexin V
(Figure 1B) suggesting that ICL formation was pivotal to the
cytotoxic effects of SJG-136.
The addition of fludarabine at a fixed molar ratio of 1:100 (SJG-
136:fludarabine) resulted in increased DNA crosslinking in the
majority of samples tested (9/10) with an average increase of 32.8%
at the 2nM concentration of SJG-136. The comparisons of DNA
crosslinking at 2nM and 4nM SJG-1367fludarabine are shown in
Figure 1C. We also performed time-course experiments using both
the comet assay and the Annexin V assay to establish the kinetics
of the DNA crosslinking and apoptosis induction in primary CLL
cells. In keeping with previous findings (Clingen et al, 2005), SJG-
136 rapidly induced DNA crosslinks and these were maximal after
24h exposure (data not shown). Apoptosis was also induced in a
time-dependent manner with clear evidence of enhanced apoptotic
cell killing in the cultures exposed to the combination of SJG-136
and fludarabine (Figure 1D). By 12h the combination was
statistically more cytotoxic than SJG-136 alone (P¼0.04) and by
24h this was even more marked (Po0.0001). This enhanced
cytotoxicity appeared greater than the summative apoptotic effects
of the two agents alone suggesting a synergistic interaction.
SJG-136 and fludarabine synergise in primary CLL cells
The cytotoxic synergy between SJG-136 and fludarabine was
assessed in all 40 samples. Figure 2A shows the dose–response
of CLL cells derived from one patient treated with various
concentrations of SJG-136 and fludarabine as single agents and
in combination. The combination of the two drugs was
significantly more cytotoxic than either single agent. Furthermore,
Figure 2B shows that the slopes of the median-effect plots for the
single drugs and the combination were not parallel, suggesting
that the two agents had different modes of action. Therefore, the
equation for the conservative isobologram was used to calculate
the combination index (CI) shown in the fraction-affected CI plot
(Figure 2C). All 40 samples showed synergy between the two drugs
at a fixed molar ratio of 1:100 (SJG-136:fludarabine) with a mean
CI of 0.5470.2. Combination index values less than 1 denote
synergy, with the smallest values representing the greatest degree
of synergy. Although the degree of synergy was significantly
diminished in patient samples defined as fludarabine resistant
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Figure 1 Percentage decrease in comet tail moment in CLL samples treated with SJG-1367fludarabine for 24h. The decrease in tail moment reflects an
increase in DNA ICL. (A) Ability of SJG-136 to produce DNA ICL in a concentration-dependent manner in the samples tested. (B) The degree of DNA
crosslinking correlated with the cytotoxic effects of SJG-136 in vitro.( C) Effect of the combination of SJG-136 and fludarabine resulting in increased DNA
crosslinking. (D) Apoptosis was markedly enhanced in a time-dependent manner in samples treated with the combination of SJG-136 and fludarabine when
compared to either drug alone. The increase in apoptosis was evident after 12h (*Po0.05) and became more marked after 24 and 48h (**Po0.0001).
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swhen compared with fludarabine-sensitive samples (P¼0.03),
synergy was still demonstrated in all these samples (mean
CI¼0.6270.3). The drug-sensitivity data for fludarabine-sensitive
and fludarabine-resistant patient groups are summarised in
Table 2. Analysis of the degree of synergy, as defined by CI
values, in prognostically distinct subsets of CLL patients revealed
that patients with unmutated VH genes, high CD38 expression and
high ZAP-70 expression all showed significantly reduced synergy
(Figure 2D). However, this observation is likely to be caused by a
greater proportion of these subsets having either in vitro or in vivo
fludarabine resistance.
Inhibition of transcription of the excision repair enzyme
ERCC1 by fludarabine
The consistent demonstration of synergy between SJG-136 and
fludarabine in this study led us to consider the possible mechanism
that potentiated this effect. It has previously been demonstrated
that fludarabine can inhibit DNA repair mechanisms and thereby
synergise with cisplatin in the human chronic myeloid leukaemic
K562 cell line (Yang et al, 1995; Li et al, 1997). More recently,
Clingen et al (2005) reported that the XPF-ERCC1 endonuclease
contributes to the repair of SJG-136-induced minor groove DNA
ICL in Chinese hamster ovary (CHO) cells. Therefore, we
hypothesised that fludarabine may suppress ERCC1 transcription
and thereby enhance the cytotoxic effects of SJG-136. We first
analysed serial dilutions of cDNA derived from CLL patient RNA
to compare the efficiency of the PCR amplification reactions for
ERCC1 and S14 (Figure 3A). It could be demonstrated in three
independent experiments that both PCR ran with almost identical
amplification efficiency, which is a prerequisite for using the change
in crossing point (DCt) method for relative quantitation (Winer
et al, 1999). To take into account the variation in total RNA
introduced into each reaction, transcripts of S14 were quantified as
an endogenous RNA control, and each sample was normalised on
the basis of its S14 content. In addition, the relative amounts of
ERCC1 and S14 were also normalised to a control sample (untreated
cells). There was interpatient variability in terms of the magnitude
of change in ERCC1 transcription following exposure to both
fludarabine and SJG-136 (Figure 3B). However, fludarabine
suppressed ERCC1 transcription in the majority of samples (15/
20) and SJG-136 caused an increase in ERCC1 transcription (20/20)
when compared to controls. Analysis of all 20 patients studied
(Figure 3C) confirmed that fludarabine significantly suppressed
ERCC1 transcription (P¼0.04), SJG-136 significantly induced
ERCC1 transcription (Po0.0001) and the combination of fludar-
abine and SJG-136 resulted in a suppression of ERCC1 transcription
when compared to SJG-136 alone (P¼0.001).
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Figure 2 Synergistic cytotoxicity produced by SJG-136 and fludarabine in primary CLL cells. (A) Dose–response curves were generated for CLL cells
treated with SJG-136 and/or fludarabine. The cytotoxicity was quantified using an Annexin V/propidium iodide assay. (B) Median-effect plot. The cells were
treated for 48h with SJG-136 (1.0, 2.5, 5.0, 7.5, 10.0, 20.0 or 50nM), fludarabine (0.1, 0.25, 0.5, 0.75, 1.0, 2.0 or 5.0mM), or both at a fixed molar ratio of
1:100. The median-effect plot was constructed using Calcusyn software where Fa is the fraction affected and Fu the fraction unaffected. The fraction-
affected CI plot was constructed by computer analysis of the data in (B) using the conservative isobologram (C). Combination index values of o1 occurred
at a wide range of inhibition levels, indicating that synergy was produced by the combination. (D) Analysis of prognostic subsets revealed that there was
diminished synergy in samples derived from patients with unmutated VH genes, high CD38 expression and high ZAP-70 expression. However, this is likely to
be the result of a preponderance of these samples demonstrating in vitro or in vivo fludarabine resistance.
Table 2 Mean drug sensitivity data for the fludarabine sensitive and
fludarabine resistant subsets of CLL samples in the study
CLL Patient samples
Mean
fludarabine
LD50
Mean SJG-136
LD50
Mean
CI
Fludarabine sensitive (n¼20) 0.8mM70.5mM 8.5nM73.0nM 0.4770.2
Fludarabine resistant (n¼20) 1.7mM70.6mM 10.2nM73.2nM 0.6270.3
P-value 0.004* 0.13 0.03*
CI¼combination index; CLL¼chronic lymphocytic leukaemia. *Statistical significance
at Po0.05 level.
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sSuppression of ERCC1 transcription correlates with the
degree of synergy observed with SJG-136
We next investigated whether fludarabine-mediated suppression of
ERCC1 transcription was mechanistically relevant to the synergy
observed between SJG-136 and fludarabine. To do this, we
compared the percentage reduction in ERCC1 transcription
induced by fludarabine in each patient sample with the degree
of synergy between SJG-136 and fludarabine as measured by the
CI. Figure 4A shows the positive correlation between these two
parameters suggesting a mechanistic link between increased
suppression of ERCC1 transcription and enhanced synergy
between the two drugs. Further evidence for this association was
derived from subset analysis of the fludarabine-sensitive and
fludarabine-resistant patient groups. The diminished degree of
synergy demonstrated in the fludarabine-resistant subset was
strongly associated with the reduced capacity of fludarabine to
suppress ERCC1 transcription (Figure 4B and C). However, the
retention of synergy in these samples indicates that the mechan-
isms that underpin the synergistic interaction between fludarabine
and SJG-136 are more complex than the transcriptional regulation
of one excision repair enzyme.
DISCUSSION
In this study, we set out to establish whether fludarabine could
enhance the DNA ICL capacity of SJG-136 in primary human CLL
cells and thereby offer a rationale for its clinical use in
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Figure 4 Relationship between change in ERCC1 transcription and the
degree of synergy between SJG-136 and fludarabine. (A) The percentage
change in ERCC1 transcription induced by fludarabine correlated with the
degree of synergy observed between SJG-136 and fludarabine as measured
by CI. (B) The fludarabine-sensitive samples showed a significant increased
ability to suppress ERCC1 transcription when compared with the
fludarabine-resistant subset (Po0.0001). (C) This resulted in significantly
diminished synergy in the fludarabine-resistant subset (P¼0.03).
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scombination with SJG-136. Using a modified comet assay to
measure DNA crosslinking, we demonstrated that SJG-136 is an
efficient, concentration-dependent, ICL-inducing agent in primary
CLL cells. Importantly, the level of ICL correlated with sensitivity
to SJG-136, suggesting a causal link between this critical lesion and
cytotoxicity. Time course analysis revealed that the percentage of
SJG-136-induced ICL was similar at both 24 and 48h (data not
shown). These results are in accord with those described by
Hartley et al (2004), who showed that SJG-136-induced DNA ICL
persisted both in vitro and in vivo when compared to those
produced by conventional major groove binding drugs inferring
that the kinetics of the repair of SJG-136-induced DNA cross-
linking are very slow. However, co-incubation of SJG-136 and
fludarabine resulted in an enhanced DNA crosslinking profile in
the majority of the CLL cell samples tested (9/10), indicating that
the combination may be more cytotoxic than SJG-136 alone.
Consequently, the next question that we wanted to address was
to establish whether fludarabine could synergise with SJG-136 to
induce more effective cell killing in primary human CLL cells.
All of the samples tested (n¼40) at the experimentally optimised
1:100 fixed molar ratio (SJG-136:fludarabine) demonstrated a
high level of synergy (mean CI¼0.5470.2). Importantly, this
synergistic relationship, albeit diminished, was retained even in
samples derived from patients with either in vitro or in vivo
fludarabine resistance (mean CI¼0.6270.3). The fludarabine-
resistant subset was characterised by a predominance of samples
derived from patients with poor prognostic markers; unmutated
VH genes (16/20), high CD38 expression (14/20) and high ZAP-70
expression (12/20). As a result, subset analysis of these groups
revealed statistically diminished synergy between SJG-136 and
fludarabine in all of these poor prognostic subsets. However,
synergy was retained in these poor risk groups, suggesting that the
combination of SJG-136 and fludarabine may be particularly useful
in these patients as well as in the salvage of fludarabine-resistant
disease.
Previous work has shown that fludarabine can inhibit the repair
of cisplatin- and oxaliplatin-induced DNA crosslinking (Yang et al,
1995; Li et al, 1997; Moufarij et al, 2006). Importantly, this appears
to be more marked in CLL cells when compared to normal
lymphocytes (Moufarij et al, 2006). In addition, Clingen et al
(2005) demonstrated that sensitivity to SJG-136 was dependent to
some extent on ERCC1 expression in CHO cells. To determine
whether ERCC1 was induced by SJG-136 in primary CLL cells, we
performed real-time RT-PCR on RNA extracted from CLL cells
exposed to SJG-136, fludarabine and both drugs in combination.
All of the samples tested (20/20) showed a marked increase in
ERCC1 transcription in response to SJG-136 when compared to
untreated control samples. In contrast, fludarabine suppressed
ERCC1 transcription as a single agent in the majority of samples
(15/20) and inhibited SJG-136-induced ERCC1 transcription when
used in combination (20/20). Importantly, the ability of fludar-
abine to suppress ERCC1 transcription when used in combination
with SJG-136 correlated with the degree of synergy observed
between the two drugs (r
2¼0.28; P¼0.017). This indicates that
the inhibition of ERCC1 is a key mechanistic component of the
synergy between the two drugs. However, samples that showed
diminished fludarabine-mediated suppression of ERCC1 still
retained cytotoxic synergy between the two agents pointing to
additional mechanisms that contribute to their synergistic inter-
action. Taken together, our data demonstrate a clear relationship
between SJG-136-induced DNA ICL and cytotoxicity in primary
CLL cells and offer a mechanism-based rationale for the increased
DNA ICL observed in samples treated with the combination of
SJG-136 and fludarabine compared to SJG-136 alone. The retention
of cytotoxic synergy in samples derived from patients with
either in vitro or in vivo resistance to fludarabine provides a clear
indication for the use of the combination of SJG-136 and
fludarabine in the treatment of this group of patients.
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